a Division of Hypertension , the First Affiliated Hospital, and College of Clinical Medicine of Henan University of Science and Technology , Luoyang , China.
b Division of Endocrinology , Luoyang Central Hospital Affiliated to Zhengzhou University , Luoyang , China.
Clin Exp Hypertens. 2019;41(1):75-79. doi: 10.1080/10641963.2018.1445750. Epub 2018 Mar 28.
The comparison of antihypertensive effects between telmisartan and candesartan in patients with essential hypertension has been investigated in several small studies. The results were not consistent. We performed this meta-analysis determining the antihypertensive effect of telmisartan versus candesartan in these patients.
We searched Pubmed, Web of Science, and Cochrane Central for all published studies comparing the antihypertensive effects between telmisartan and candesartan in patients with essential hypertension.
The antihypertensive effects were assessed in 302 patients included in 4 trials with a mean follow-up of 10 ± 4 weeks. There were no significant differences between telmisartan and candesartan in reduction of systolic blood pressure (SBP) and diastolic BP (DBP) in patients with essential hypertension (weighted mean differences (WMD) for SBP 1.98 mm Hg (95% confidence interval (CI), -0.53, 4.49), p > 0.05; WMD for DBP 0.26 mm Hg (95% CI, -1.65, 2.16), p > 0.05), respectively. In a sub-analysis including 2 randomized studies, there was not a significant difference for the reduction of SBP (WMD 0.90 (95% CI, -2.88, 4.68) mm Hg, p > 0.05) or DBP (WMD -0.80 (95% CI, -3.40, 1.81) mm Hg, p > 0.05) treated with telmisartan or candesartan.
This meta-analysis provides the evidence that the antihypertensive effects of telmisartan and candesartan are similar on SBP and DBP reduction in patients with essential hypertension, suggesting that strict designed randomized controlled trial would be helpful to compare antihypertensive effects of angiotensin II receptor blockers (ARBs) and improve the choice of ARBs in antihypertensive therapy.
已有多项小型研究比较了替米沙坦和坎地沙坦在原发性高血压患者中的降压效果，结果并不一致。本研究旨在通过荟萃分析来确定这两种药物在原发性高血压患者中的降压效果。
我们检索了 Pubmed、Web of Science 和 Cochrane Central 数据库，以获取所有比较替米沙坦和坎地沙坦降压效果的已发表研究。
共有 4 项试验的 302 例患者纳入本研究，平均随访 10±4 周。在原发性高血压患者中，替米沙坦与坎地沙坦在收缩压（SBP）和舒张压（DBP）的降低方面无显著差异（SBP 的加权均数差（WMD）为 1.98mmHg（95%置信区间（CI），-0.53，4.49），p＞0.05；DBP 的 WMD 为 0.26mmHg（95%CI，-1.65，2.16），p＞0.05）。在包括 2 项随机研究的亚组分析中，替米沙坦和坎地沙坦在 SBP 降低方面（WMD 为 0.90mmHg（95%CI，-2.88，4.68），p＞0.05）或 DBP 降低方面（WMD -0.80mmHg（95%CI，-3.40，1.81），p＞0.05）无显著差异。
本荟萃分析结果表明，替米沙坦和坎地沙坦在原发性高血压患者的 SBP 和 DBP 降低方面的降压效果相似，提示进行严格设计的随机对照试验将有助于比较血管紧张素 II 受体阻滞剂（ARB）的降压效果，并改善降压治疗中 ARB 的选择。
